New Study Questions Effectiveness of Popular Alzheimer’s Drug Leqembi in Women

McGill researchers found lecanemab may be less effective in women, prompting calls for more personalized treatment and improved consideration of sex differences in clinical trials. Since becoming only the second Alzheimer’s-modifying drug approved by the U.S. Food and Drug Administration in 2023, lecanemab (marketed as Leqembi) has seen steadily increasing sales, reaching $87 million USD […] Read More